Recent advances in molecular positron emission tomographic imaging using novel PCa-specific agents, such as fluciclovine and prostate-specific membrane antigen, offer increased sensitivity in detecting occult metastatic disease. This evidence concerns the gene FOLH1 and metastatic neoplasm.